Fresenius Kabi Braced For ‘Pyrrhic Victory’ In Akorn Damages Lawsuit
As COVID-19 Takes A Bite Out Of Profit
Fresenius Kabi says a decision on damages stemming from its aborted takeover of troubled Akorn is expected imminently, but has underlined it will not reap enormous riches with a victory. Meanwhile, the German firm has just initiated Phase III trials for a key biosimilar candidate.
You may also be interested in...
Questions Asked After Akorn’s Sudden Shutdown
Akorn is facing questions after suddenly shutting down its operations and terminating its employees, with a chapter 7 bankruptcy filing on the cards. Answers are being sought over why the company did not provide advance warnings to employees given the precarious state of its finances.
New Fresenius Kabi Chief Sen Adds Sandoz’ Pawlu
As Michael Sen takes the reins as CEO of Fresenius Kabi, Christian Pawlu has been recruited from Sandoz to head up the firm’s generics and complex formulations unit.
Biogen Delves Deeper Into Biosimilars With Tocilizumab Partnership
Biogen has broken new ground in its biosimilar endeavors, expanding beyond its partnership with its part-owned Samsung Bioepis company by agreeing a deal for rights to Bio-Thera Solutions’ BAT1806 biosimilar Actemra/RoActemra (tocilizumab) candidate.